Roger Jeffs - Dova Pharmaceuticals Independent Director
Director
Dr. Roger A. Jeffs is Independent Director of the company. Dr. Jeffs has served as a member of our Board of Directors since May 2017. Dr. Jeffs retired as President and CoChief Executive Officer of United Therapeutics Corporation in June 2016. Prior to his retirement, Dr. Jeffs served as the CoChief Executive Officer of United Therapeutics Corporation from January 2015 to June 2016 and President of United Therapeutics Corporation from 2001 to June 2016. Dr. Jeffs joined United Therapeutics Corporation in 1998 as Director of Research, Development and Medical and also served as its Chief Operating Officer from 2001 to 2014. Prior to 1998, Dr. Jeffs worked at Amgen, Inc. as Manager of Clinical Affairs and Associate Director of Clinical Research from 1995 to 1998. Dr. Jeffs served as a Director of United Therapeutics Corporation from 2001 until June 2016, and currently serves on the Board of Directors of Albireo Pharma, Inc., Axsome Therapeutics, Sangamo Therapeutics and Axovant Sciences Ltd. Dr. Jeffs is the Lead Director of Axsome Therapeutics since 2017.
| Age | 56 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 919 748-5975 |
| Web | www.dova.com |
Roger Jeffs Latest Insider Activity
Tracking and analyzing the buying and selling activities of Roger Jeffs against Dova Pharmaceuticals stock is an integral part of due diligence when investing in Dova Pharmaceuticals. Roger Jeffs insider activity provides valuable insight into whether Dova Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Dova Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Dova Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Roger Jeffs over six months ago Acquisition by Roger Jeffs of 5681 shares of Axsome Therapeutics subject to Rule 16b-3 |
Dova Pharmaceuticals Management Efficiency
Dova Pharmaceuticals' management efficiency ratios could be used to measure how well Dova Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.25 M in liabilities with Debt to Equity (D/E) ratio of 43.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dova Pharmaceuticals has a current ratio of 5.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dova Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Dova Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dova Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dova to invest in growth at high rates of return. When we think about Dova Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Katherine Hatcher | Par Pacific Holdings | 52 | |
| Dan Dorenkamp | National CineMedia | N/A | |
| Andrew Glaze | National CineMedia | 39 | |
| Timothy Clossey | Par Pacific Holdings | 62 | |
| Scott Schneider | National CineMedia | 58 | |
| Kurt Hall | National CineMedia | 58 | |
| Mary Bullock | Genuine Parts Co | 70 | |
| Curtis Anastasio | Par Pacific Holdings | 64 | |
| Walter Dods | Par Pacific Holdings | 79 | |
| Melvin Cooper | Par Pacific Holdings | 64 | |
| Mark Segall | National CineMedia | 55 | |
| Dennis Clements | Asbury Automotive Group | 73 | |
| Philip Maritz | Asbury Automotive Group | 60 | |
| Anthony Chase | Par Pacific Holdings | 66 | |
| Paula Madison | National CineMedia | 63 | |
| Robert Loudermilk | Genuine Parts Co | 61 | |
| Scott Thompson | Asbury Automotive Group | 57 | |
| Lawrence Goodman | National CineMedia | 63 | |
| Joel Alsfine | Asbury Automotive Group | 51 | |
| Christine Thorp | Par Pacific Holdings | N/A | |
| Jenner Wood | Genuine Parts Co | 66 | |
Management Performance
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -1.0E-4 |
Dova Pharmaceuticals Leadership Team
Elected by the shareholders, the Dova Pharmaceuticals' board of directors comprises two types of representatives: Dova Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dova. The board's role is to monitor Dova Pharmaceuticals' management team and ensure that shareholders' interests are well served. Dova Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dova Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Goldman, Independent Director | ||
| Douglas Blankenship, CFO | ||
| Alfred Novak, Independent Director | ||
| Alex Sapir, President CEO, Director | ||
| Lee Allen, Chief Medical Officer | ||
| Sean Stalfort, Director | ||
| Kevin Laliberte, Senior Vice President - Product Development | ||
| Roger Jeffs, Independent Director | ||
| David Zaccardelli, President CEO | ||
| Nancy Wysenski, Independent Director | ||
| Mark Hahn, CFO, Principal Financial Officer and Principal Accounting Officer | ||
| Paul Manning, Chairman of the Board | ||
| Jason Hoitt, Chief Commercial Officer |
Dova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dova Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | (0.06) % | |||
| Operating Margin | (541.38) % | |||
| Current Valuation | 380.37 M | |||
| Shares Outstanding | 28.8 M | |||
| Shares Owned By Insiders | 62.25 % | |||
| Shares Owned By Institutions | 40.63 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Earning | (12.63) X |
Pair Trading with Dova Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dova Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dova Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Johnson Johnson could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Johnson Johnson when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Johnson Johnson - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Johnson Johnson to buy it.
The correlation of Johnson Johnson is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Johnson Johnson moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Johnson Johnson moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Johnson Johnson can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Dova Stock
If you are still planning to invest in Dova Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dova Pharmaceuticals' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |